

Table S1. Clinical characteristics and treatment outcomes of the drug resistant isolates in the study.

| Case | Age (years) | Sex | Region | HIV Status | FLDs Resistance Pattern | SLD Resistance Pattern | <i>M.tb</i> Lineage; Spoligo Family | Treatment Outcome |
|------|-------------|-----|---------|------------|-------------------------|------------------------|-------------------------------------|-------------------|
| 1 | 24 | F | North | Negative | H; R; E | Susceptible | L2; Beijing | Completed |
| 2 | 35 | M | North | Negative | H; R; E; S | Susceptible | L2; Beijing | Completed |
| 3 | 43 | F | South | Positive | H; R; | Susceptible | L4; S | LTFU |
| 4 | 24 | F | South | Negative | H; R; E; S | Susceptible | L4; LAM3 | Completed |
| 5 | 17 | F | South | Negative | H; R | Susceptible | L4; X3 | Cured |
| 6 | Unknown | F | South | Positive | R | Susceptible | L4; S | LTFU |
| 7 | 60 | M | South | Positive | H | Susceptible | L4; LAM3 | LTFU |
| 8 | 1 | M | Central | Unknown | H | Susceptible | L4; LAM4 | LTFU |
| 9 | 30 | M | Central | Positive | H; R | Susceptible | L4; LAM3 | Not Initiated |
| 10 | 32 | M | South | Unknown | H | Susceptible | L4; S | LTFU |
| 11 | 35 | F | Central | Positive | H; R; E; S | Susceptible | L2; Beijing | Cured |
| 12 | 54 | M | North | Positive | H; R | Susceptible | L2; Beijing | Deceased |
| 13 | 23 | M | South | Negative | H; R; S | Susceptible | L4; LAM3 | Completed |
| 14 | 33 | M | South | Positive | H; R; E; S | Susceptible | L4; S | Not Initiated |
| 15 | 39 | M | South | Positive | R | Susceptible | L4; X3 | Cured |
| 16 | 40 | M | North | Positive | H; R; E; S | Susceptible | L2; Beijing | Completed |
| 17 | 42 | M | South | Positive | H; R; E; S | Susceptible | L4; T1 | Completed |
| 18 | 32 | F | North | Positive | H; R; E | Susceptible | L2; Beijing | Completed |
| 19 | 28 | M | South | Negative | H; R; E; S | Susceptible | L2; Beijing | Cured |
| 20 | 63 | M | South | Negative | H; R | Susceptible | L4; X3 | Cured |
| 21 | 72 | F | South | Negative | R | Susceptible | L4; S | Completed |
| 22 | 18 | F | Central | Unknown | H; R | Susceptible | L4; LAM3 | Defaulted |
| 23 | 49 | M | North | Negative | H; R; E; S | Susceptible | L1; EAI | Completed |
| 24 | 52 | M | North | Positive | H; R | Susceptible | L2; Beijing | Deceased |
| 25 | 53 | M | North | Unknown | H | Susceptible | L2; Beijing | LTFU |
| 26 | 56 | M | South | Unknown | H; R; E; S | Susceptible | L4; LAM3 | Cured |
| 27 | 30 | F | North | Positive | H; R | Susceptible | L2; Beijing | Completed |
| 28 | 19 | F | South | Negative | R | Susceptible | L4; X3 | LTFU |
| 29 | 36 | F | Central | Negative | R | Susceptible | L4; T1 | Completed |
| 30 | 40 | M | Central | Positive | H; R; E; S | Susceptible | L1; EAI1_SOM | Completed |
| 31 | 59 | M | South | Negative | H; R; E; S | Susceptible | L1; EAI1_SOM | Cured |
| 32 | 15 | F | Central | Positive | H; R | Susceptible | L4; X2 | Completed |



| | | | | | | | | |
|----|----|---|---------|----------|------------|-------------|------------------|---------------|
| 33 | 34 | F | South | Positive | H; R; E; S | Susceptible | Unknown; unknown | Deceased |
| 34 | 40 | F | Central | Positive | H; R; E; S | Susceptible | L1; EAI1_SOM | Failure |
| 35 | 32 | F | Central | Positive | H; R; E | Susceptible | L4; X2 | Completed |
| 36 | 32 | M | South | Positive | H; R; E | Susceptible | L2; Beijing | LTFU |
| 37 | 36 | M | South | Negative | H | Susceptible | L4; T1 | Deceased |
| 38 | 13 | M | North | Unknown | R | Susceptible | L4; T3 | LTFU |
| 39 | 33 | M | South | Positive | R | Susceptible | L4; S | Not Initiated |
| 40 | 35 | M | Central | Positive | R | Susceptible | L4; S | Completed |
| 41 | 21 | F | South | Negative | R | Susceptible | L4; T2-T3 | LTFU |
| 42 | 33 | F | South | Unknown | H; R; E; S | Susceptible | L4; X3 | Completed |
| 43 | 37 | F | Central | Positive | H; R; E; S | Susceptible | L1; EAI1_SOM | Completed |
| 44 | 8 | F | North | Unknown | H | Susceptible | L4; S | LTFU |
| 45 | 7 | M | North | Negative | H; R; E | Susceptible | L4; LAM1 | Completed |
| 46 | 43 | F | North | Positive | H; R; S | Susceptible | L4; X3 | Completed |
| 47 | 47 | M | North | Positive | R | Susceptible | L4; LAM3 | Completed |
| 48 | 40 | M | Central | Positive | R | Susceptible | L4; X3 | LTFU |
| 49 | 41 | M | South | Unknown | H; R; E; S | Susceptible | L4; LAM11_ZWE | Completed |
| 50 | 27 | F | South | Positive | H; R; E; S | Susceptible | L4; LAM11_ZWE | Completed |

LTFU: Lost to follow up; H: Isoniazid; R: Rifampicin; S: Streptomycin; E: Ethambutol; L1: Lineage 1; L2: Lineage 2; L4: Lineage 4